AbelZeta Pharma has announced that AstraZeneca (AZ) will acquire the company's remaining 50% share of the development and commercialisation rights to C-CAR031 in China, granting AZ exclusive global rights to the therapy. Under the agreement, AbelZeta is eligible to receive up to USD 630 million, including an upfront payment and development, regulatory and sales milestone payments related to the Chinese market. The company remains eligible for additional milestones and royalties from AZ for the development of the asset in the rest of the world.
C-CAR031 is an autologous CAR-T therapy targeting GPC3, a protein associated with hepatocellular carcinoma (HCC) and other solid tumours. The therapy incorporates AZ's dominant negative TGF-β receptor II armouring platform. This transaction consolidates AZ's control over the global development pathway for C-CAR031, which is currently under investigation for the treatment of HCC.
PharmCube's NextBiopharm® database shows that Big Pharma companies have entered into six collaborations with Chinese CAR-T developers. Click here to request a free trial for NextBiopharm®.
